Table. Sensitivity Analyses on Sales Return on Investment, by Number of Postapproval Trials for Extension of Indications or Dosage Forms.

Clinical Trial Phases	No. of Postapproval Trials
	0 (Base Case)	1	2	3	4	5
Additional R&D, No., US$ millions
All phases	0	39	78	117	156	195
Phases II-III	0	34	69	103	137	172
Income return on investment, median (range), US$ millions
All phases	14.5 (3.3-55.1)	13.8 (3.3-46.7)	13.1 (3.2-40.4)	12.5 (3.2-35.6)	11.9 (3.1-31.8)	11.4 (3.1-28.7)
Phases II-III	14.5 (3.3-55.1)	13.8 (3.3-47.5)	13.3 (3.2-41.7)	12.7 (3.2-37.2)	12.2 (3.1-33.5)	11.7 (3.1-30.5)

Abbreviation: R&D, research and development.